Latest Biotech News

Pfizer presented additional mid-stage data supporting monthly dosing for berobenatide, its GLP-1 receptor agonist acquired from Metsera. At ADA 2026, Pfizer described results from VESPER-3 showing...

Roche said it plans to start a Phase 2 study evaluating a combination of two investigational obesity drugs—petrelintide and enicepatide—during the year. The company positioned the pairing as a...

The World Health Organization unveiled a six-month plan to contain a current Bundibugyo Ebola outbreak in Africa, including scaling point-of-care molecular diagnostics and strengthening reference...

Fulcrum Therapeutics moved to discontinue its lead sickle cell disease program, pociredir, after the FDA raised concerns about the benefit-risk profile, including a link to unexpectedly high rates...

The US Supreme Court unanimously ruled in Hikma’s favor in a patent dispute over its “skinny label” generic version of Amarin’s Vascepa. The court held Hikma’s generic did not infringe Amarin’s...

Photocure agreed to acquire Vesica Health for $30.5 million, adding urine-based molecular diagnostics to its bladder cancer portfolio. The deal includes cash and stock payments, with...

Finerenone produced positive Phase III results in adults with chronic kidney disease caused by glomerular diseases without diabetes, according to the FIND-CKD trial. The study reported that...

Medable launched an Agentic Accelerator Program intended to help life sciences organizations deploy agentic AI across clinical development. The initiative offers onboarding, integration support,...

Contraceptive developer Contraline raised $92.5 million to advance two male birth control candidates, including a once-daily topical gel and an implantable option. The financing underscores...

Pfizer and Roche both used ADA26 to push incremental dose-and-combination narratives for their obesity programs. Pfizer presented additional data supporting monthly dosing of berobenatide...

Roche disclosed mid-stage clinical data for a daily incretin shot in type 1 diabetes, a disease state where GLP-1-based drugs are not typically viewed as a direct solution. The company’s Phase 2...

Policy and process issues resurfaced as stakeholders pushed for faster clinical-trial review timelines. A House committee directed the FDA to reform how it signs off on new INDs, reflecting...

Takeda took a $2.5 billion Japanese yen legal charge after a pay-for-delay antitrust verdict in Boston. A federal jury found Takeda liable in a class-action case tied to Amitiza (constipation...

Ona Therapeutics continued to build its ADC-focused obesity-adjacent strategy?—no, this cluster should be obesity funding—actually the market signal here is biotech venture capital. Multiple...

The WHO unveiled a six-month plan to stamp out the ongoing Bundibugyo Ebola outbreak, including scaling a point-of-care molecular testing system. WHO is partnering with Africa CDC, FIND, Unitaid,...

Fulcrum Therapeutics laid off the majority of its workforce and discontinued development of pociredir for sickle cell disease following an FDA-raised benefit-risk concerns. The company’s SEC...

The U.S. Supreme Court sided with Hikma Pharmaceuticals in a unanimous decision involving its ‘skinny label’ generic version of Amarin’s Vascepa. The ruling held that Hikma’s product did not...

Deal flow continued to concentrate in complex modalities like ADCs and targeted immunology. Agios reached a potential $665 million agreement with Oscotec for cevidoplenib, an oral SYK inhibitor in...

Biotech companies continued to expand molecular monitoring capabilities through collaborations. Natera partnered with CytoDyn to evaluate circulating tumor DNA dynamics in metastatic colorectal...

The House Appropriations Committee directed the FDA to reform how it signs off on new INDs, citing the need for the U.S. to keep pace with China and other countries developing therapies. The push...